Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis

Clinical and Experimental Nephrology

Volumn 14, Issue 2, 2010, Pages 158-163

  Nagaya, Hiroshi ^a   Inaguma, Daijo ^a   Kitagawa, Akimitsu ^a   Murata, Minako ^a   Kamimura, Yutaka ^a   Hamaguchi, Kyoko ^a   Tatematsu, Miho ^a   Suzuki, Sachiyo ^a   Kurata, Kei ^a   Yuzawa, Yukio ^b   Matsuo, Seiichi ^b  

^a TOSEI GENERAL HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Darbepoetin alfa; Hemodialysis; Interval of administration

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

AGED; ANEMIA; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; MALE; NEPHROSCLEROSIS; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL;

AGED; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 77952876072     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-009-0251-x     Document Type: Article

References (13)

1. IC Macdougall 2001 An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP) Nephrol Dial Transplant 16 14 21 10.1093/ndt/16.1.14 1:CAS:528:DC%2BD3MXlslWhurk%3D 11402086
2. Y Vanrenterghem P Barany JFE Mann PG Kerr J Wilson NF Baker SJ Gray European/Australian NESP 970200 Study Group 2002 Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients Kidney Int 62 2167 2175 10.1046/j.1523-1755.2002. 00657.x 1:CAS:528:DC%2BD38XpsFKlur0%3D 12427142 (Pubitemid 35366172)
3. F Locatelli B Canaud F Giacardy A Martin-Malo N Baker J Wilson 2003 Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEPO) Nephrol Dial Transplant 18 362 369 10.1093/ndt/18.2.362 1:CAS:528:DC%2BD3sXisVCls7s%3D 12543893 (Pubitemid 36181689)
4. F Carrera L Oliveira P Maia T Mendes C Ferreira 2006 The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis Nephrol Dial Transplant 21 2846 2850 10.1093/ndt/gfl387 1:CAS:528:DC%2BD28XhtVWltrbO 16891642 (Pubitemid 44542241)
5. P Ajima J Bommer B Canaud F Carrera K Eckardt WH Horl RT Krediet KF Locatelli IC Macdougall B Wikstrom 2001 Practical guidelines for the use of NESP in treating renal anemia Nephrol Dial Transplant 16 22 28
6. JC Egrie E Dwyer JK Broene A Hitz MA Lykos 2003 Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin Exp Hematol 31 290 299 10.1016/S0301-472X(03)00006-7 1:CAS:528:DC%2BD3sXislChtro%3D 12691916 (Pubitemid 36407605)
7. ND Vaziri 2004 Oxidative stress in uremia: nature, mechanism, and potential consequences Semin Nephrol 24 5 469 473 10.1016/j.semnephrol.2004.06. 026 1:CAS:528:DC%2BD2cXhtVCgsrfI 15490413 (Pubitemid 39361056)
8. F Gejyo A Saito T Akizawa T Akiba T Sakai M Suzuki S Nishi Y Tsubakihara H Hirakata M Bessho Japanese Society for Dialysis Therapy 2004 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients Ther Apher Dial 8 443 459 10.1111/j.1774-9987.2004.00199.x 15663544
9. T Akizawa S Koshikawa M Iwasaki the KRN321 A08 Study Group 2007 Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese patients Ther Apher Dial 11 220 226 10.1111/j.1744-9987.2007.00474.x 1:CAS:528:DC%2BD2sXns1ars7s%3D 17498005 (Pubitemid 46716166)
10. J Mimic-Oka A Savic-Radojevic M Pljesa-Ercegovac M Opacic T Simic N Dimkovic PV Simic 2005 Evaluation of oxidative stress after repeated intravenous iron supplementation Ren Fail 27 345 351 1:CAS:528:DC%2BD2MXks1ehtr8%3D 15957553
11. ME Rodrigue I Brochu P Dorleans-Juste R Lavivierea M Lebel 2008 Effect of erythropoietin on blood pressure and on the vascular endothelial ET-1/ETB receptor system Am J Hypertens 21 639 643 10.1038/ajh.2008.37 1:CAS:528:DC%2BD1cXmt1yjsbw%3D 18437122 (Pubitemid 351733379)
12. M Kanbay A Akcay T Delibasi B Uz A Kaya C Koca F Turgut N Bavbek E Uz M Duranay R Yigitoglu 2007 Comparison of effect of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure Adv Ther 24 346 352 10.1007/BF02849903 1:CAS:528:DC%2BD2sXot1eisbo%3D 17565925 (Pubitemid 46988378)
13. LA Szczech HX Barnhart JK Inrig DN Reddan S Sapp RM Califf UD Patel AK Singh 2008 Secondary analysis of the CHOIR trial epoetin-a dose and achieved hemoglobin outcomes Kidney Int 74 791 798 10.1038/ki.2008.295 1:CAS:528:DC%2BD1cXhtVGgtbjN 18596733